Laboratorios Farmaceúticos Rovi SA (LABFF)
65.86
0.00 (0.00%)
USD |
OTCM |
Dec 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.369B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.66% |
| Valuation | |
| PE Ratio | 24.71 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.198 |
| Price to Book Value | 4.612 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.093 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1988 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.96% |
Profile
| Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain. |
| URL | http://www.rovi.es |
| Investor Relations URL | N/A |
| HQ State/Province | Madrid |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 15, 2025 |
Ratings
Profile
| Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain. |
| URL | http://www.rovi.es |
| Investor Relations URL | N/A |
| HQ State/Province | Madrid |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 15, 2025 |